Abstract
An investigator may be asked to conduct a study with a new molecular entity which has never been administered to man before, or else has only been administered to a small number of subjects in Phase I studies. Alternatively, he may undertake a trial during Phase II or III, when there is already a considerable amount of clinical data available.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Cohen, A., Posner, J. (1995). What does the investigator need to know about the drug?. In: Cohen, A., Posner, J. (eds) A Guide to Clinical Drug Research. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-8463-0_3
Download citation
DOI: https://doi.org/10.1007/978-94-015-8463-0_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-015-8465-4
Online ISBN: 978-94-015-8463-0
eBook Packages: Springer Book Archive